INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation

Omeros shares plunged 19.12% to close at $8.67 on June 26, 2026 after the EMA/CHMP adopted a negative opinion on the company’s marketing authorization application for narsoplimab in TA-TMA. Pomerantz LLP is investigating whether Omeros and certain officers/directors engaged in securities fraud or other unlawful practices. The news likely increases downside risk for equity holders and regulatory/clinical approval prospects.

Analysis

This is less a litigation event than a financing event in disguise. For a single-asset/near-single-asset biotech, a meaningful EU regulatory setback can compress the probability-weighted NPV far more than the headline move implies, because it weakens ex-U.S. partnering leverage, raises the odds of a more dilutive capital raise, and shifts investor attention from launch timing to runway. The class-action process mostly adds a slow-burn overhang, but it also keeps disclosure risk alive and can deter risk capital until the next clean clinical/regulatory datapoint.

Near term, the stock can remain mechanically pressured for days to weeks because biotech holders tend to de-risk first and litigate later; the litigation itself is not the main driver. Over 1-3 months, the key catalyst is whether management can produce a credible path around the negative opinion—appeal, additional data, or a reframed regulatory strategy—because absent that, the market will likely price a higher dilution discount. Over 6-18 months, the real issue is whether this becomes a terminal setback for the ex-U.S. commercial story rather than a temporary setback, which would keep the multiple below peers with broader label optionality.

Contrarianly, the move may be somewhat overdone if investors are treating the legal investigation as incremental downside rather than a lagging symptom of a bigger regulatory shock. If there is still a viable U.S. or alternate-execution path, the equity could stabilize once forced sellers clear, especially if cash burn is manageable. The thesis would be falsified by a concrete regulatory reversal, credible new data that reopens the EMA path, or a capital-markets transaction that eliminates near-term dilution risk.

Key Decisions for Investors

• Short OMER on any relief rally over the next 1-3 weeks; use a tight stop above the post-news gap area, because the trade is really about fading a degraded probability of EU monetization and potential financing pressure.
• If options are liquid, buy 1-3 month OMER put spreads instead of outright puts to express the downside while capping theta burn; this is a cleaner way to monetize a slow litigation/regulatory grind lower.
• Watch for any announced partnership, financing, or amended regulatory strategy over the next 30-90 days; if the company secures non-dilutive capital or a credible appeal path, cover shorts quickly because the market will re-rate runway risk first.
• Relative-value idea: short OMER against a basket of higher-quality commercial-stage biotech names or IBB/XBI as a hedge if you want to isolate company-specific regulatory and legal risk rather than take sector beta.